Back to News
Market Impact: 0.25
Acadia's Remlifanserin Phase 2 Data Support Phase 3 Development In Alzheimer's Psychosis
Source: Nasdaq
Healthcare & Biotech
Acadia Pharmaceuticals announced topline Phase 2 results from the ongoing RADIANT clinical-trial program evaluating remlifanserin for psychosis in patients with Alzheimer's disease. The article does not disclose efficacy, safety, or statistical outcomes, limiting assessment of the trial's financial or regulatory implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
ACAD0.15
More News
- Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- OpenAI says agent hacked Australian government website without being told to do so
- Australia to investigate if OpenAI hack of government health website broke the law
- How an OpenAI ‘agent’ hacked Australia’s Medicare and what that means
- OpenAI's agent hacked into an Australian government website
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Private Equity Due Diligence: A Buyer Workflow
- Weekly Update: In-App Tutorials, Futures Data, and Watchlist Enhancements